Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer

50 Studies Every Urologist Should Know Pub Date : 2021-02-01 DOI:10.1093/MED/9780190655341.003.0015

J. Zabell

引用次数: 21

Abstract

This chapter summarizes the findings of landmark TAX 327 trial in men with castrate-refractory prostate cancer who received either docetaxel (weekly or every 3 weeks) or mitoxantrone (every 3 weeks). The study found improved overall survival, better quality of life, and similar side effects in men treated with docetaxel.

查看原文本刊更多论文

多西紫杉醇加强的松或米托蒽醌加强的松治疗晚期前列腺癌

本章总结了具有里程碑意义的TAX 327试验的结果，该试验在接受多西他赛(每周一次或每3周一次)或米托蒽醌(每3周一次)治疗的去势难治性前列腺癌男性患者中进行。研究发现，接受多西他赛治疗的男性总体生存率提高，生活质量提高，副作用相似。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

50 Studies Every Urologist Should Know

自引率

0.00%

发文量